Готові списки джерел за темами / G13D

Добірка наукової літератури з теми "G13D"

Автор: Grafiati
Опубліковано: 10 грудня 2022
Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "G13D".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "G13D"

1

Rojo, Federico, Trinidad Caldes, Sandra Zazo, Miguel de la Hoya, Cristina Carames, Atocha Romero, Gloria Serrano, et al. "Prevalence of low-penetrance KRAS (codons 12/13 and 61) and BRAF mutations in metastatic colorectal carcinoma." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e14147-e14147. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14147.

Повний текст джерела
Анотація:
e14147 Background: In patients with metastatic colorectal cancer (mCRC), activating mutations within KRAS, which result in EGFR-independent intracellular signal transduction activation, are found in approximately 35-40% of patients with mCRC have been significantly associated with lack of response to cetuximab or panitumumab therapy. Although current guidelines recommend testing for frequent KRAS codons 12/13 mutations, emerging data indicate that additional KRAS and BRAF mutations are also predictive of non-responsiveness to anti-EGFR antibodies in mCRC. This study is aimed to analyze the prevalence of low-penetrance KRAS and BRAF V600 mutations in caucasian mCRC population. Methods: A two-institution retrospective cohort of 1,238 consecutive KRAS wild type mCRC patients previously studied for 7 mutations in codons 12/13 (G12D, G12A, G12V, G12S, G12R, G12C and G13D) by the CE-IVD marked ARMS-scorpion real-time polymerase chain reaction PCR (Therascreen, Qiagen) was assayed by the diagnostic TaqMelt PCR assay cobas KRAS mutation and cobas BRAF V600 mutation tests (Roche), which are designed to detect 19 mutations in KRAS codons 12, 13 and 61 (including G12F, G13C, G13R, G13S, G13A, G13V, G13I, Q61H, Q61K, Q61R, Q61L, Q61E and Q61P) and BRAF V600 (V600E, V600K and V600D) mutations. An additional cohort of 146 KRAS mutated patients by ARMS-scorpion PCR was studied. DNA was obtained by cobas DNA preparation kit from one single 5µm formalin-fixed paraffin-embedded tissue section. Results: In all samples, sufficient DNA was obtained for KRAS and BRAF mutational studies. Among 1238 KRAS codons 12/13 wild-type patients by ARMS-scorpion PCR,166 (13.4%) showed KRAS mutations, 117 (9.5%) in codons 12/13, and 49 (4%) in codon 61. BRAF V600 mutations were detected in 9% cases. In ARMS-scorpion PCR KRAS mutated patients, mutations were confirmed by cobas in all cases. Conclusions: The cobas mutation tests are robust and reproducible assays that, 1) detects a higher incidence (13.4%) of mutations in codons 12, 13, and 61 of the KRAS gene in wild-type mCRC population, 2) a relevant rate of BRAF mutations is present in the same population, and 3) requires a very small amount of tissue.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Rabara, Dana, Timothy H. Tran, Srisathiyanarayanan Dharmaiah, Robert M. Stephens, Frank McCormick, Dhirendra K. Simanshu, and Matthew Holderfield. "KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis." Proceedings of the National Academy of Sciences 116, no. 44 (October 14, 2019): 22122–31. http://dx.doi.org/10.1073/pnas.1908353116.

Повний текст джерела
Анотація:
KRAS mutations occur in ∼35% of colorectal cancers and promote tumor growth by constitutively activating the mitogen-activated protein kinase (MAPK) pathway. KRAS mutations at codons 12, 13, or 61 are thought to prevent GAP protein-stimulated GTP hydrolysis and render KRAS-mutated colorectal cancers unresponsive to epidermal growth factor receptor (EGFR) inhibitors. We report here that KRAS G13-mutated cancer cells are frequently comutated with NF1 GAP but NF1 is rarely mutated in cancers with KRAS codon 12 or 61 mutations. Neurofibromin protein (encoded by the NF1 gene) hydrolyzes GTP directly in complex with KRAS G13D, and KRAS G13D-mutated cells can respond to EGFR inhibitors in a neurofibromin-dependent manner. Structures of the wild type and G13D mutant of KRAS in complex with neurofibromin (RasGAP domain) provide the structural basis for neurofibromin-mediated GTP hydrolysis. These results reveal that KRAS G13D is responsive to neurofibromin-stimulated hydrolysis and suggest that a subset of KRAS G13-mutated colorectal cancers that are neurofibromin-competent may respond to EGFR therapies.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Lee, Hyo Joo, Bonhan Koo, Yoon Ok Jang, Huifang Liu, Thuy Nguyen Thi Dao, Seok-Byung Lim, and Yong Shin. "Hot-Spot-Specific Probe (HSSP) for Rapid and Accurate Detection of KRAS Mutations in Colorectal Cancer." Biosensors 12, no. 8 (August 4, 2022): 597. http://dx.doi.org/10.3390/bios12080597.

Повний текст джерела
Анотація:
Detection of oncogene mutations has significance for early diagnosis, customized treatment, treatment progression, and drug resistance monitoring. Here, we introduce a rapid, sensitive, and specific mutation detection assay based on the hot-spot-specific probe (HSSP), with improved clinical utility compared to conventional technologies. We designed HSSP to recognize KRAS mutations in the DNA of colorectal cancer tissues (HSSP-G12D (GGT→GAT) and HSSP-G13D (GGC→GAC)) by integration with real-time PCR. During the PCR analysis, HSSP attaches to the target mutation sequence for interference with the amplification. Then, we determine the mutation detection efficiency by calculating the difference in the cycle threshold (Ct) values between HSSP-G12D and HSSP-G13D. The limit of detection to detect KRAS mutations (G12D and G13D) was 5–10% of the mutant allele in wild-type populations. This is superior to the conventional methods (≥30% mutant allele). In addition, this technology takes a short time (less than 1.5 h), and the cost of one sample is as low as USD 2. We verified clinical utility using 69 tissue samples from colorectal cancer patients. The clinical sensitivity and specificity of the HSSP assay were higher (84% for G12D and 92% for G13D) compared to the direct sequencing assay (80%). Therefore, HSSP, in combination with real-time PCR, provides a rapid, highly sensitive, specific, and low-cost assay for detecting cancer-related mutations. Compared to the gold standard methods such as NGS, this technique shows the possibility of the field application of rapid mutation detection and may be useful in a variety of applications, such as customized treatment and cancer monitoring.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Lopez Ruitti, Paula, Ruben Salanova, Julieta Nafissi, Guillermo Rabossi, Guillermo Bramuglia, and Yanina Powazniak. "Mutational status of KRAS and BRAF of an Argentinian population of colorectal tumors." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e14109-e14109. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14109.

Повний текст джерела
Анотація:
e14109 Background: Activating mutation of the KRAS oncogene is an established predictive biomarker for resistance to anti–epidermal growth factor receptor (anti-EGFR) therapies in advanced colorectal cancer (CRC). BRAF, another component of the EGFR-MAPK signal transduction pathway, is also subject to a common activating mutation in CRC. The aim of this report is to present the mutational status of KRAS, BRAF of an Argentinian population of CR tumors. Methods: Tumor blocks were obtained from 85 consenting patients of various public and private hospitals. We analyzed the presence of KRAS point mutations in codons 12 and 13, and the BRAF-V600E from formalin paraffin fixed sections with Polymerase Chain Reaction (PCR) amplification-sequencing. Results: From a total of 85 patients, 46% F and 54% M, with a median age of 64 years (range, 28-85), 72% (61) where found to be wild type, while the other 28% (24) showed the KRAS mutation in the following amino acids: G12V 30% (7), G12D 17% (4), G12C 17% (4), G12S 9% (2), G12A 4% (1), G13D 25% (6). We analyzed in 45 patients the mutational status of BRAF-V600E, 29 patients presented BRAF and KRAS wild type, 12 had a KRAS mutation while the BRAF was wild type, and 4 patients reveled a mutation of BRAF in the presence of a KRAS wild type. Conclusions: The type of mutation observed in this study corresponds to the findings of previous studies, where the most common KRAS mutation detected was G12V in codon 12 followed by G13D in codon 13. A preliminary report based in 146 patients from Argentine (Perazzo F, et al. 2009) revealed marked differences in KRAS mutation rates compared to our findings, showing the following percentage of mutations: G12V 62% vs. 30% , G12D 26% vs. 17% and G13R 1.7% vs. 0%, G13D 0% vs. 25%, respectively. BRAF mutational status was according to international and national reports.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Yuan, Ye, Yingting Liu, Ye Wu, Junling Zhang, Chunti Shen, Feng Zhang, Changping Wu, and Wenwei Hu. "Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients." International Journal of Biological Markers 36, no. 2 (May 27, 2021): 33–39. http://dx.doi.org/10.1177/17246008211017152.

Повний текст джерела
Анотація:
Background: The KRAS mutations are high-frequency somatic mutations found in colorectal cancer patients from Western and Asian countries however, with the exception of exon 2 of KRAS, other prevalence and prognostic values have not been adequately assessed in Asian patients. The aim of this study was to determine the mutation frequencies of whole exon mutations of KRAS in Chinese colorectal cancer patients and to investigate their impact on prognosis. Methods: A total of 7189 tumor tissue samples (iCohort) were subjected to next-generation sequencing for detection of KRAS mutations. All pathologic or likely pathologic mutations of KRAS were considered. In addition, clinical features and prognostic dates were collected from 145 patients at The Third Affiliated Hospital of Soochow University, China (sCohort) and used droplet digital™ polymerase chain reaction to detect KRAS mutations. Results: In the iCohort, 2706 patients (37.6%) were confirmed harboring KRAS mutations. The most frequent of these mutations were G12D (32.19%), G12V (17.96%), and G13D (17.59%). In the sCohort, 51 colorectal cancer patients (35.17%) had KRAS mutations, among which KRAS G12D (64.71%), G13D (29.41%), and G14D (3.92%) were high-frequency. The KRAS mutations were associated with shorter median overall survival than wild-type tumors (69 vs. 55 months; HR 1.80; 95% Cl 1.22, 2.64; P=0.0003). In the Cox multivariate analysis, age (HR 1.562; 95% Cl 1.10, 2.22; P=0.013), tumor differentiation (HR 0.417; 95% Cl 0.19, 0.90; P=0.026), and KRAS mutation (HR 1.897; 95% Cl 0.19, 0.90; P=0.001) remained independent predictors of shorter overall survival. Among the common KRAS mutations, G12D was significantly associated with shorter overall survival (HR 2.17; 95% Cl 1.31, 3.58; P < 0.0001) compared with KRAS wild-type patients. Conclusions: Our findings indicate that KRAS genes are frequently mutated, and over 30% harbored the KRAS G12D mutation subtype. We found that the KRAS G12D mutation is associated with inferior survival and is a biomarker of poor prognosis in Chinese patients. Our data emphasize the importance of molecular features in colorectal cancer patients, which could potentially be improved by G12D-specific related inhibitors.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Attoye, Bukola, Matthew Baker, Chantevy Pou, Fiona Thomson, and Damion K. Corrigan. "Electrochemical DNA Detection Methods to Measure Circulating Tumour DNA for Enhanced Diagnosis and Monitoring of Cancer." Proceedings 60, no. 1 (November 2, 2020): 15. http://dx.doi.org/10.3390/iecb2020-07067.

Повний текст джерела
Анотація:
Liquid biopsies are becoming increasingly important as a potential replacement for existing biopsy procedures which can be invasive, painful and compromised by tumour heterogeneity. This paper reports a simple electrochemical approach tailored towards point-of-care cancer detection and treatment monitoring from biofluids using a label-free detection strategy. The mutations under test were the KRAS G12D and G13D mutations, which are both important in the development and progression of many human cancers and which have a presence that correlates with poor outcomes. These common circulating tumour markers were investigated in clinical samples and amplified by standard and specialist PCR methodologies for subsequent electrochemical detection. Following pre-treatment of the sensor to present a clean surface, DNA probes developed specifically for detection of the KRAS G12D and G13D mutations were immobilized onto low-cost carbon electrodes using diazonium chemistry and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride/N-hydroxysuccinimide coupling. Following the functionalisation of the sensor, it was possible to sensitively and specifically detect a mutant KRAS G13D PCR product against a background of wild-type KRAS DNA from the representative cancer sample. Our findings give rise to the basis of a simple and very low-cost system for measuring ctDNA biomarkers in patient samples. The current time to result of the system was 3.5 h with considerable scope for optimisation, and it already compares favourably to the UK National Health Service biopsy service where patients can wait weeks for their result. This paper reports the technical developments we made in the production of consistent carbon surfaces for functionalisation, assay performance data for KRAS G13D and detection of PCR amplicons under ambient conditions.
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Salem, Mohamed E., Scott Kopetz, Josep Tabernero, Frank A. Sinicrope, Myriam Chalabi, Jeanne Tie, Kunal C. Kadakia, et al. "Comprehensive characterization of KRAS mutations and inter-relation with primary tumor location in colorectal cancers." Journal of Clinical Oncology 41, no. 4_suppl (February 1, 2023): 231. http://dx.doi.org/10.1200/jco.2023.41.4_suppl.231.

Повний текст джерела
Анотація:
231 Background: The recent development of KRAS G12C inhibitors underscores the potential to target KRAS mutations. Right-sided and left-sided colon tumors (RT and LT) exhibit different molecular features. We characterize the prevalence of KRAS-variants, interrelation with primary tumor location, and association with immune biomarkers in CRC. Methods: We retrospectively reviewed CRC tumors of all stages (with known sidedness) that underwent NGS with the Tempus xT assay (DNA-seq of 648 genes at 500x coverage, full transcriptome RNA-seq). Bivariate analyses were performed to compare KRAS alterations, immune biomarkers, and co-mutations by tumor location. P-values comparing individual co-mutations between groups were adjusted for false discovery (FDR). Results: A total of 3,391 CRC were analyzed (RT: n = 442 [13%], transverse: n = 116 [3%], LT; n = 2,833 [84%]) of which 1486 (44%) tumors harbored KRAS mutations. Overall, KRAS mutations were more frequent in RT compared to transverse tumors and LT (52% vs 41% vs 43%, p<0.001, respectively). The most frequent KRAS mutation variants observed were G12D (29 %), G12V (22%), G13D (16%), and G12C (5.7%). There was no significant difference in the prevalence of KRAS variant types between LT and RT (p=0.5). Significant differences in genomic co-mutations with various KRAS variants were observed in the following genes: TP53, FBXW7, and NF1 (FDR- P<0.05). RT and transverse tumors were more likely have MSI-H and TMB-H (>10 mut/mb) status than LT (MSI-H: 18% vs 22% vs 2.2% and TMB-H (20% vs 22% vs 3%, P<0.001), respectively. CRC tumors harboring G13D variants were more likely to be associated with and MSI-H and TMB-H status (and 7.7% and 8.5%) compared to G12D (2.8 % and 3.9 %), G12V (1.8 % and 2.1%), and G12C (0% and 2.4%); P = 0.003 and 0.001. Conclusions: The most frequent KRAS mutation variants observed in CRC tumors were G12D, G12V, G13D, and G12C. There was no significant difference in the prevalence of KRAS variant types between tumors of the left vs right colon. CRC tumors that harbored G13D variants were significantly more likely to be associated with MSI-H and TMB-H status. [Table: see text]
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Tahir, Raiha, Santosh Renuse, Savita Udainiya, Anil K. Madugundu, Jevon A. Cutler, Raja Sekhar Nirujogi, Chan Hyun Na, Yaoyu Xu, Xinyan Wu, and Akhilesh Pandey. "Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles." Journal of Proteome Research 20, no. 1 (September 28, 2020): 670–83. http://dx.doi.org/10.1021/acs.jproteome.0c00587.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Musselwhite, Laura W., Sally J. Trufan, Kunal C. Kadakia, Jimmy J. Hwang, and Mohamed E. Salem. "The prevalence of common KRAS variants and associated outcomes in patients with metastatic colorectal cancer (mCRC)." Journal of Clinical Oncology 40, no. 4_suppl (February 1, 2022): 173. http://dx.doi.org/10.1200/jco.2022.40.4_suppl.173.

Повний текст джерела
Анотація:
173 Background: KRAS is the most common driver oncogene in mCRC. Comprehensive analysis of KRAS variants prevalence and the relationship between variants and outcomes are lacking. Herein, we aimed to examine the impact of KRAS variants on outcomes in patients (pts) with mCRC. Methods: A retrospective review of pts with mCRC with known KRAS mutation status was performed. Fisher’s exact test was used to analyze the association between KRAS variants. Cox Proportional Hazard modeling was used to study the relationship between KRAS variants and overall survival (OS). Kaplan-Meier method was used to assess OS. Results: A total of 423 pts diagnosed with mCRC from 2014-2020 with available extended KRAS status were evaluated. Median age at diagnosis was 59.8 yrs (22.3-92 range), 57% were male, 22% were Black, and 75% presented with de novo metastatic disease. A majority (56%) of tumors harbored KRAS mutations. The most frequent KRAS variants were G12D 47% (111), G12V 12% (28), G12C 13% (31), G13D 9% (21), and 20% (47) were other variants. In univariate analyses, the presence of a KRAS mutation, Black race, de novo metastatic disease, age, receipt of chemotherapy, and receipt of surgery were associated with OS. Tumor location was not associated with OS. In multivariable analyses, mutation type was a significant predictor of death and the presence of G12D was associated with an increased risk of death compared to G12V and KRAS wildtype. There was no increased risk of death in pairwise comparisons of G12D and G13D or other KRAS variants. Black race, de novo metastatic disease, and no receipt of surgery were additional independent predictors of death (Table). With a median follow-up of 25.7 months (mo.), median OS was 35.5 mo. (95% CI 10.5-50.9) with G12C, Not Reached (NR) (95% CI 21-NR) with G12V, 36.2 mo. (95%CI 14.9-58.5) with G13D, 26.2 mo. (95% CI 21.8-37) with G12D, 39.6 mo. (95% CI 22.4-47.9) for other KRAS mutations, and 59.6 mo. (95%CI 48.2-NA) for KRAS wildtype, respectively (p=0.0003). Conclusions: Our findings highlight differences in unadjusted overall survival when comparing G12D to some other KRAS variants. Codon and amino acid-specific mutations of KRAS should be considered when evaluating prognosis and further study on treatment effects and sequencing is warranted. [Table: see text]
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Tejpar, Sabine, Ilhan Celik, Michael Schlichting, Ute Sartorius, Carsten Bokemeyer, and Eric Van Cutsem. "Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab." Journal of Clinical Oncology 30, no. 29 (October 10, 2012): 3570–77. http://dx.doi.org/10.1200/jco.2012.42.2592.

Повний текст джерела
Анотація:
Purpose We investigated in the first-line setting our previous finding that patients with chemorefractory KRAS G13D–mutated metastatic colorectal cancer (mCRC) benefit from cetuximab treatment. Methods Associations between tumor KRAS mutation status (wild-type, G13D, G12V, or other mutations) and progression-free survival (PFS), survival, and response were investigated in pooled data from 1,378 evaluable patients from the CRYSTAL and OPUS studies. Multivariate analysis correcting for differences in baseline prognostic factors was performed. Results Of 533 patients (39%) with KRAS-mutant tumors, 83 (16%) had G13D, 125 (23%) had G12V, and 325 (61%) had other mutations. Significant variations in treatment effects were found for tumor response (P = .005) and PFS (P = .046) in patients with G13D-mutant tumors versus all other mutations (including G12V). Within KRAS mutation subgroups, cetuximab plus chemotherapy versus chemotherapy alone significantly improved PFS (median, 7.4 v 6.0 months; hazard ratio [HR], 0.47; P = .039) and tumor response (40.5% v 22.0%; odds ratio, 3.38; P = .042) but not survival (median, 15.4 v 14.7 months; HR, 0.89; P = .68) in patients with G13D-mutant tumors. Patients with G12V and other mutations did not benefit from this treatment combination. Patients with KRAS G13D–mutated tumors receiving chemotherapy alone experienced worse outcomes (response, 22.0% v 43.2%; odds ratio, 0.40; P = .032) than those with other mutations. Effects were similar in the separate CRYSTAL and OPUS studies. Conclusion The addition of cetuximab to first-line chemotherapy seems to benefit patients with KRAS G13D–mutant tumors. Relative treatment effects were similar to those in patients with KRAS wild-type tumors but with lower absolute values.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "G13D"

1

Wu, Ning. "Structural analysis of oncogenic H-Ras mutants G12A and G13A." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape7/PQDD_0019/MQ45880.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Althoff, Till [Verfasser]. "Gq/G11- und G12/G13-Protein-vermittelte Signaltransduktion im Kontext kardiovaskulärer Erkrankungsprozesse / Till Althoff." Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2021. http://d-nb.info/1232240745/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Chitapi, Itai. "The structure of testis angiotensin-converting enzyme (tACE-g13) in complex with the inhibitor RXPA380." Master's thesis, University of Cape Town, 2006. http://hdl.handle.net/11427/4248.

Повний текст джерела
Анотація:
Includes bibliographical references.
Angiotensin-converting enzyme (ACE), a zinc metalloprotease, is a key regulator of the mammalian renin-angiotensin system (RAS) Primarily, ACF is a dipeptidl peptidase which cleaves angiotensin I to produce angiotensin II, a potent vasoconstrictor. By the same enzymatic mechanism, ACE also inactivates the vasodilator bradykinin. The main overall effect of these actions is an increase in blood pressure. Several ACF inhibitors have been developed as drugs for the treatment of myocardial infarction, hypertension, kidney failure and heart failure.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Carboué, Quentin. "Mise au point d'un bioréacteur de fermentation en milieu solide fonctionnant en continu pour la production de métabolites secondaires antioxydants par Aspergillus niger G131." Thesis, Aix-Marseille, 2018. http://www.theses.fr/2018AIXM0136.

Повний текст джерела
Анотація:
Aspergillus niger souche G131 est un champignon qui produit en quantité des métabolites secondaires appartenant à la famille des naphtho-gamma-pyrones (NγPs). Ces NγPs sont des pigments qui présentent des intérêts industriels de par leurs importants potentiels antiradicalaires. L’objectif de ce doctorat est la production à l’échelle pilote et en continu de NγPs à travers la culture du champignon sur milieu solide. Le choix de la fermentation en milieu solide (FMS) comme processus de culture repose sur des aspects d’ordre qualitatif et quantitatif de production, ainsi que sur des raisons économiques et éthiques, relatives à la protection de l’environnement avec notamment la possibilité de valoriser des coproduits agricoles comme milieu de culture pour le champignon. Dans un premier temps, ce travail s’intéresse à la caractérisation de la composition et des potentialités associées aux molécules produites par la souche. Ces potentialités incluent les activités anti-radicalaires et les mesures de cytotoxicité. La thèse porte également sur la caractérisation de la physiologie de croissance de la souche en FMS et sur l’optimisation des conditions de culture par la méthodologie des plans d’expériences pour l’augmentation de la production de NγPs. Une stratégie originale d’optimisation adaptée aux contraintes posées par la FMS est d’ailleurs proposée. Finalement, un transfert d’échelle de production est réalisé au moyen d’un bioréacteur prototype innovant permettant la production à l’échelle pilote de milieu fermenté en continu. Dans son dernier chapitre, ce travail s’intéresse donc à la mise au point des paramètres opératifs qui entourent la production continue de NγPs par FMS
Aspergillus niger strain G131 is a non-ochratoxigenic filamentous fungus producing high quantities of secondary metabolites known as naphtha-gamma-pyrones (NγPs). NγPs are pigments of industrial interest in reason of their high antioxidant properties. The aim of this dissertation is the continuous, pilote-scaled production of these NγPs through the cultivation of the fungus on solid medium. The choice of solid state fermentation (SSF) as cultivation method is not only driven by quantitative and qualitative considerations, but also by economical and ethical concerns related to environmental protection. SSF allows, in fact, a direct valorization of agricultural byproducts as the solid medium for the fungal growth. First, this work deals with the characterization of the composition and potentialities associated with the molecules produced by the strain, which include antioxidant and cytotoxic activities. Second, the dissertation focuses on the characterization of the fungal growth’s physiology on solid medium and on the optimization of the culture conditions using experimental methodology in order to increase NγPs production. For this purpose, an original optimization strategy is proposed to overcome specific constraints connected to SSF. Finally, a scale transfer of the production is advanced by means of an innovative prototype bioreactor continuously producing fermented material. The final chapter of this work addresses the development of parameters regarding the continuous NγPs production using SSF
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Gaillard, Anne. "Impact des caractéristiques cliniques des clients sur le contre-transfert des thérapeutes." Thesis, Université Laval, 2011. http://www.theses.ulaval.ca/2011/27823/27823.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Gagné, Guillaume. "Avancées technologiques des miroirs liquides inclinables." Thesis, Université Laval, 2007. http://www.theses.ulaval.ca/2007/24891/24891.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Gagnon, Anne-Marie. "La puissance de l'imagination." Thesis, Université Laval, 2009. http://www.theses.ulaval.ca/2009/26440/26440.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Baumgart, Anja [Verfasser], Bernhard [Akademischer Betreuer] Küster, and Tobias N. [Akademischer Betreuer] Dechow. "Die Rolle der Notch-Signaltransduktion bei der Tumorgenese des nicht-kleinzelligen Bronchialkarzinoms in vitro und im KRAS-G12D-induzierten Mausmodell / Anja Baumgart. Gutachter: Tobias N. Dechow. Betreuer: Bernhard Küster." München : Universitätsbibliothek der TU München, 2011. http://d-nb.info/1019588454/34.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Gagnon, Rémy. "Du déploiement de l'individualité ou genèse du singulier par le vouloir-exister." Thesis, Université Laval, 2006. http://www.theses.ulaval.ca/2006/24129/24129.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Gagnon, Josée. "Consommation de lait et syndrome métabolique chez la femme ménopausée." Thesis, Université Laval, 2007. http://www.theses.ulaval.ca/2007/24248/24248.pdf.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "G13D"

1

Ning, Wu. Structural analysis of oncogenic H-Ras mutants G12A and G13A. Ottawa: National Library of Canada, 1999.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Acp Deutsch Heute-G131/132 Iupu. Cengage Heinle, 2016.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Koenig, Mike, Hubert Michalski, Mariusz Motyka, and Stefan Draminksi. Panzerjäger 38: Hetzer and G13. Kangero, Oficyna Wydawnicza, 2014.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Ar G13 New Works Old Friends: Grades K-3. Renaissance Learning Inc, 2001.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

A, Iverson Ronald, Darr Bridget, U.S. Fish and Wildlife Service, and Partners for Wildlife Program, eds. Partners for Wildlife Program springs enhancement: Agreement #14-48-11333-99-G135, John McDonagh, grantee. [Yreka, Calif: U.S. Fish and Wildlife Service, Partners for Wildlife Program, 2001.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Geological Survey (U.S.), ed. Distribution and taxonomy of late Quaternary diatoms from gravity cores L13-81-G117, L13-81-G138, L13-81-G145, and TT197-G330, northern California continental slope. Menlo Park, CA: U.S. Dept. of the Interior, U.S. Geological Survey, 1993.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Geological Survey (U.S.), ed. Distribution and taxonomy of late Quaternary diatoms from gravity cores L13-81-G117, L13-81-G138, L13-81-G145, and TT197-G330, northern California continental slope. Menlo Park, CA: U.S. Dept. of the Interior, U.S. Geological Survey, 1993.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Geological Survey (U.S.), ed. Distribution and taxonomy of late Quaternary diatoms from gravity cores L13-81-G117, L13-81-G138, L13-81-G145, and TT197-G330, northern California continental slope. Menlo Park, CA: U.S. Dept. of the Interior, U.S. Geological Survey, 1993.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "G13D"

1

Broadis, Emily, and Stuart J. O’Toole. "G13 Continent Catheterisable Conduit." In Basic Techniques in Pediatric Surgery, 471–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-20641-2_142.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Habbe, Nils, R. A. Meguid, V. Fendrich, G. Feldmann, R. H. Hruban, S. D. Leach, and A. Maitra. "Die Überexpression der onkogenen Kras-Mutation G12D im adulten Pankreas führt zur Entstehung von highgrade PanIN-Läsionen in Ela-CreERT2;LSL-KrasG12D-Mäusen." In Chirurgisches Forum 2008, 27–28. Berlin, Heidelberg: Springer Berlin Heidelberg, 2008. http://dx.doi.org/10.1007/978-3-540-78833-1_8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

"G12α and G13α." In Encyclopedia of Signaling Molecules, 1946. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-67199-4_101377.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Pascual, Juan M. "Glut1 Deficiency (G1D)." In Movement Disorders, 785–95. Elsevier, 2015. http://dx.doi.org/10.1016/b978-0-12-405195-9.00050-0.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Offermanns, S. "G12/G13 Family." In Encyclopedia of Biological Chemistry, 343–46. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-12-378630-2.00318-2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Offermanns, Stefan. "G12/G13 Family." In Reference Module in Life Sciences. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-819460-7.00108-0.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Offermanns, Stefan. "G12/G13 Family." In Encyclopedia of Biological Chemistry, 158–61. Elsevier, 2004. http://dx.doi.org/10.1016/b0-12-443710-9/00300-8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Offermanns, Stefan. "G13 G Protein." In xPharm: The Comprehensive Pharmacology Reference, 1–4. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.60593-8.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

"Tombs Fondo Azzolini necropolis (G1–3) Public tombs: honouring the elite (G4–12) Cult of the dead (G13–14) Eumachia’s tomb: changes over time (G15–19) Tomb of the Lucretii Valentes: fight for survival of a family." In Pompeii, 151–52. Routledge, 2004. http://dx.doi.org/10.4324/9780203506080-20.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "G13D"

1

McFall, Thomas, and Edward C. Stites. "Abstract 37: Computational analysis of the KRAS G13D colorectal cancer response to EGFR inhibition with an alternatively parameterized model." In Abstracts: AACR Special Conference on Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies; January 9-12, 2020; San Diego, CA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.advprecmed20-37.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Furness, L., P. Riley, and T. Briggs. "G139(P) The boy with the disappearing bones." In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference and exhibition, 13–15 May 2019, ICC, Birmingham, Paediatrics: pathways to a brighter future. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-rcpch.135.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Galllagher, K., and W. Kelsall. "G136(P) Marketing paediatrics – an inter-generational collaboration." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 13–15 March 2018, SEC, Glasgow, Children First – Ethics, Morality and Advocacy in Childhood, The Journal of the Royal College of Paediatrics and Child Health. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2018. http://dx.doi.org/10.1136/archdischild-2018-rcpch.132.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Uhomoibhi, C., H. Bedford, and A. Pearce. "G133(P) Reducing social inequalities in childhood vaccination uptake." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 24–26 May 2017, ICC, Birmingham. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2017. http://dx.doi.org/10.1136/archdischild-2017-313087.132.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Abidin, N., D. Jayachandran, and P. Shah. "G134 Oral propranolol in the management of infantile haemangiomas." In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference and exhibition, 13–15 May 2019, ICC, Birmingham, Paediatrics: pathways to a brighter future. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-rcpch.130.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

O’Sullivan, GM, VM Shivamurthy, K. Semkova, and JE Mellerio. "G136 An unusual case of alopecia in a toddler." In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference and exhibition, 13–15 May 2019, ICC, Birmingham, Paediatrics: pathways to a brighter future. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-rcpch.132.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Evans, S., R. Mills, and T. Ninan. "G138(P) Acute bronchiolitis: variations in intravenous fluid administration." In Royal College of Paediatrics and Child Health, Abstracts of the Annual Conference, 13–15 March 2018, SEC, Glasgow, Children First – Ethics, Morality and Advocacy in Childhood, The Journal of the Royal College of Paediatrics and Child Health. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2018. http://dx.doi.org/10.1136/archdischild-2018-rcpch.134.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Kurek, Krzysztof. "The Deuteron Spin-Dependent Structure Function g1d." In 15th International Workshop on Deep-Inelastic Scattering and Related Subjects. Amsterdam: Science Wise Publishing, 2007. http://dx.doi.org/10.3360/dis.2007.79.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Eickel, Bianca, and Richard Perassi. "A evolução do posicionamento da comunicação gráfico-simbólica da marca tecnológica Multilaser." In LINK 2021. Tuwhera Open Access, 2021. http://dx.doi.org/10.24135/link2021.v2i1.97.g133.

Повний текст джерела
Анотація:
Com o processo de globalização, o conceito de tecnologia é amplamente difundido na construção de uma sociedade mais simplificada. A tecnologia torna-se um fenômeno global no século 21, com o uso de computadores capazes de mudar o dia a dia das pessoas. Com o tempo, a tecnologia evolui e se transforma, nesse processo a comunicação e a cultura acompanham as mudanças. As empresas inseridas na sociedade e cultura atuais buscam se comunicar com os consumidores em todos os momentos; por isso, o posicionamento é irrefutável neste processo de marketing. Se a tecnologia, a comunicação e a cultura mudam com o tempo, o posicionamento da marca também deve acompanhar esse movimento. A partir deste contexto, o tema desta proposta irá descrever o processo de evolução do posicionamento da comunicação gráfico-simbólica da marca tecnológica Multilaser e, assim, analisar as mudanças de posicionamento sob a perspectiva do design. A marca escolhida traz relevância ao estudo, pois passou por diversos marcos históricos que contribuirão para a análise descritiva da evolução. A empresa foi fundada por Israel Ostrowiecki no Brasil, em 1987. Começou a atuar no segmento de impressoras e fotocopiadoras, reciclando cartuchos para impressoras até 2003. Após vários fatos históricos em sua trajetória, atualmente possui 44 mil pontos de venda no Brasil, com um portfólio de 15 departamentos, incluindo smartphones, celulares, gamers, drones, automotivo, entre outros. A problemática da proposta leva em consideração o grande volume de importação de produtos tecnológicos pelo Brasil e, assim, o estudo se justifica pela necessidade de avaliar a percepção de uma hipertrofia da função estética na comunicação do segmento tecnológico brasileiro. Para alcançar este resultado, será utilizada uma abordagem metodológica qualitativa, voltada para a percepção de significados intrínsecos às crenças, valores e atitudes nas relações humanas. Portanto, para atingir os objetivos da pesquisa, o estudo será dividido em três etapas de desenvolvimento, sendo a primeira a etapa exploratória, com a busca de artigos e livros que contribuam para a pesquisa bibliográfica e a análise descritiva de produtos de comunicação, impressos ou digitais, selecionados dentre a marca Multilaser. Para a segunda etapa, será realizada uma pesquisa bibliográfica, visando elaborar a construção do referencial teórico a partir dos materiais identificados na etapa anterior. A terceira etapa é a documental, para analisar e descrever as mudanças no posicionamento da marca sob a óptica da concepção dos documentos selecionados na primeira etapa. As discussões nesta proposta trazem a comunicação visual, aspectos históricos do termo tecnologia e sobre a empresa Multilaser; depois, a relação entre comunicação e cultura, que irá elucidar a trajetória da comunicação visual como forma de posicionamento da marca, bem como a representação gráfica publicidade na comunicação na perspectiva do design. O estudo se limitará a produtos gráficos de comunicação publicitária, onde se pretende compreender um olhar sobre o avanço do conhecimento na visualidade das marcas tecnológicas brasileiras, a atuação dos profissionais da área de design, e ainda pretende-se promover novas pesquisas que estabeleçam um posicionamento gráfico-simbólico para a tecnologia brasileira.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Nascimento, Raul Batista, and Valzeli Sampaio. "Prenda da Mangueira (Português)." In LINK 2021. Tuwhera Open Access, 2021. http://dx.doi.org/10.24135/link2021.v2i1.100.g139.

Повний текст джерела
Анотація:
O projeto Mangueira Desejo já nos traz a observação da nossa realidade atual através de um digital alternativo, trazendo de volta e dando novos significados às mangueiras, a partir da ideia do projeto Wish Tree, de Yoko Ono que incentiva a nos expressarmos através dos desejos escritos pendurado em qualquer árvore viva. Para aquelas pessoas que viveram em tempos de pouca ou nenhuma Internet, as árvores ainda tinham algum significado e importância, ou eram um pontos de referência físicos e palcos para as crianças se reunirem e brincarem sob seus abrigos. Muitas das nossas já conhecidas brincadeiras infantis nasceram, foram ensinadas e aprendidas nesse cenário, junto com um punhado de lembranças nostálgicas que estão cada vez mais difíceis de serem resgatadas, devido à diminuição do contato social trazido por diversos fatores do nosso modo de vida atual. A intenção da proposta é dar uma nova expressão ao Mangueira Desejo: que seja uma nova narrativa, possivelmente global, para trazer o propósito lúdico da árvore de volta às nossas vidas. A partir de uma conhecida brincadeira infantil brasileira, chamada “boca de forno”, que consiste em uma das crianças ser a líder, que se chamará “mãe” — encarregada de encaminhar as demandas alheias a serem atendidas pelas demais crianças o mais rápido possível. Quando começa, é cantada uma música comandada pela mamãe, e as outras seguem com a sua parte. Há muitas variantes dessa música, e essa é uma delas: Mãe: “boca de forno!” Outras: “forno!”; Mãe: “jacarandá!” Outras: “dá!”; Mãe: “quando eu mandar!” Outras: “para!”; Mãe: “e não é para?” Outras: “apanha um bolo!”; Mãe: “Raimundinho, Raimundinho, eu quero que vocês me tragam...” Após esta última estrofe, a “mãe” pede que seja encontrado algum objeto comum. Depois que cada criança trouxer o que foi pedido, a última é punida com um tapa na mão. Com base nesta brincadeira, um Alternate Reality Game (ARG) seria desenvolvido, no qual, por meio dessas mensagens digitais penduradas, pessoas ao redor do mundo poderiam trazer suas próprias memórias na forma de um jogo antigo que costumavam jogar quando crianças. Existe uma margem para as pessoas depositarem suas demandas para que outros executem, ou mesmo a natureza, interpretada pelos designers, sendo a “mãe” que exige o que precisa e deixando-as pendurados como folhas a serem levadas pelos jogadores, que resolverão e carregarão uma foto ou um vídeo em um site existente, como prova. Novos elementos podem ser adicionados para envolver melhor os jogadores, como lista de classificação, conquistas, pontuação, etc. ARGs são jogos analógicos transmídia que reúnem uma comunidade para interagir e jogar, resolvendo quebra-cabeças, mistérios, missões, e assim por diante. Todos eles têm uma narrativa forte, que amplia nossa realidade atual. O jogo é normalmente gerenciado por seus designers.
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "G13D"

1

Adhikari, Krishna. Measurement of the Spin Structure Function g1D of the Deuteron and its Moments at Low Q2. Office of Scientific and Technical Information (OSTI), December 2013. http://dx.doi.org/10.2172/1432792.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Spiers, Donald, Arieh Gertler, Harold Johnson, and James Spain. An In Vitro and In Vivo Investigation of the Diverse Biological Activities of Bovine Placental Lactogen. United States Department of Agriculture, August 1993. http://dx.doi.org/10.32747/1993.7568087.bard.

Повний текст джерела
Анотація:
In order to understand the structure-function relationship of bovine placental lactogen (bPL) and initiate production of material for in vivo testing, 28 different bPL analogues were prepared by either truncation or site-directed mutagenesis. The effect of these mutations was determined by measuring binding capacity, ability to homodimerize extracellular domains (ECDs) of several lactogenic and somatogenic receptors, and by in vitro bioassays. Two analogues were prepared in large amounts for in vivo studies. These studies (a) identified the residues responsible for the somatogenic activity of bPL (K73, G133, T188) and for both lactogenic and somatogenic activity (N-terminus, K185, Y190); (b) allowed preparation of bPL analogues with selectively abolished or reduced somatogenic activity; and (c) provided a tool to understand the kinetic difference between lactogenic and somatogenic receptors. In vivo studies using rodent and dairy models showed that bovine growth hormone (bGH) is superior to bPL in stimulating growth and lactation. Likewise, bGH has greater somatogenic activity in different age groups and thermal environments. Initial studies of bPL analog T188 suggest that its lactogenic potential is superior to bGH. Effective experimental models have now been developed and tested for analysis of new bPL analogs.
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "G13D" для конкретних типів джерел:
Статті в журналах Дисертації
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії